Phase 3 Clinical Trials With Primary Completion Dates in May 2017

This is a list of Phase 3 trials with primary completion dates in May 2017 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
ACOR Acorda Therapeutics, Inc. 2017-05-01 Phase 3 NCT02352363 Randomized Safety Study of CVT-301 Compared to an Observational Control Group
ENDP Endo International plc 2017-05-01 Phase 3 NCT01784848 GAstric Bypass to Treat obEse Patients With steAdy hYpertension
MMSI Merit Medical Systems, Inc. 2017-05-01 Phase 3 NCT01789840 Prostate Artery Embolization With Embosphere Microspheres Compared to TURP for Benign Prostatic Hyperplasia
NURO NeuroMetrix, Inc. 2017-05-01 Phase 3 NCT02809846 Quell Opioid Reduction and Pain Relief in Patients With Cancer
PBYI Puma Biotechnology Inc 2017-05-01 Phase 3 NCT01808573 A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting
PODD Insulet Corporation 2017-05-01 Phase 3 NCT02561078 An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus
PRTK Paratek Pharmaceuticals, Inc. 2017-05-01 Phase 3 NCT02877927 Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSI
SUPN Supernus Pharmaceuticals, Inc. 2017-05-01 Phase 3 NCT02618434 Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)
TBPH Theravance Biopharma, Inc. 2017-05-01 Phase 3 NCT02518139 A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
XBIT XBiotech Inc. 2017-05-01 Phase 3 NCT01767857 A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer